FR2181776A1 - - Google Patents

Info

Publication number
FR2181776A1
FR2181776A1 FR7307157A FR7307157A FR2181776A1 FR 2181776 A1 FR2181776 A1 FR 2181776A1 FR 7307157 A FR7307157 A FR 7307157A FR 7307157 A FR7307157 A FR 7307157A FR 2181776 A1 FR2181776 A1 FR 2181776A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7307157A
Other languages
French (fr)
Other versions
FR2181776B1 (ru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Pfizer Inc
Original Assignee
Pfizer Corp
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp, Pfizer Inc filed Critical Pfizer Corp
Publication of FR2181776A1 publication Critical patent/FR2181776A1/fr
Application granted granted Critical
Publication of FR2181776B1 publication Critical patent/FR2181776B1/fr
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FR7307157A 1972-02-29 1973-02-28 Expired FR2181776B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
GB5162972 1972-11-08

Publications (2)

Publication Number Publication Date
FR2181776A1 true FR2181776A1 (ru) 1973-12-07
FR2181776B1 FR2181776B1 (ru) 1976-08-13

Family

ID=26242776

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7307157A Expired FR2181776B1 (ru) 1972-02-29 1973-02-28

Country Status (16)

Country Link
US (1) US3890319A (ru)
JP (2) JPS5754516B2 (ru)
AR (1) AR213705A1 (ru)
AU (1) AU471598B2 (ru)
BE (1) BE795970A (ru)
CA (1) CA981678A (ru)
CH (2) CH576975A5 (ru)
DE (1) DE2309160A1 (ru)
ES (2) ES411804A1 (ru)
FI (1) FI63757C (ru)
FR (1) FR2181776B1 (ru)
GB (1) GB1381979A (ru)
IE (1) IE37519B1 (ru)
MX (1) MX3042E (ru)
NL (1) NL159102B (ru)
SE (1) SE417204B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0775134A1 (en) * 1994-08-04 1997-05-28 Synaptic Pharmaceutical Corporation Imidazolin-2-ylaminobenzimidazole derivatives

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
US4145421A (en) 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
US4486432A (en) * 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS6118950U (ja) * 1984-07-10 1986-02-03 財団法人鉄道総合技術研究所 トロリ線の給油装置
JPS63296814A (ja) * 1987-05-29 1988-12-02 Ishigaki Kiko Kk 集塵装置における濾材の目詰り除去装置
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
WO1995010280A1 (en) * 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
AU699041B2 (en) * 1993-12-17 1998-11-19 Board Of Regents Of The University Of Nebraska, The 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
DK0735877T3 (da) * 1993-12-17 2000-11-06 Procter & Gamble 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
NZ281460A (en) * 1994-02-08 1996-10-28 Alcon Lab Inc Processes for preparation of clonidine derivatives, intermediate complexes and process for preparation of the intermediates
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
DE69732244T2 (de) 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
JP2001506981A (ja) * 1996-11-25 2001-05-29 ザ プロクター アンド ギャンブル カンパニー α―2アドレナリン受容体作動薬として有用な2―イミダゾリニルアミノインドール化合物
WO1998023612A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
BR9713537A (pt) * 1996-11-25 2000-03-21 Procter & Gamble omo agonistas a alfa-2-adrenorreceptor
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
CN1284073A (zh) 1997-11-24 2001-02-14 宝洁公司 5-(2-咪唑啉基氨基)-苯并咪唑衍生物,其制备和作为具有改进的代谢稳定性的a-肾上腺素能受体激动剂的应用
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002005853A2 (en) 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
BR0112461A (pt) * 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
ATE429216T1 (de) * 2002-10-08 2009-05-15 Allergan Inc Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
PL376347A1 (en) * 2002-10-08 2005-12-27 Allergan, Inc. Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
BRPI0413381A (pt) 2003-08-07 2006-10-17 Allergan Inc composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
EP1660090B1 (en) * 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
DK1761266T3 (da) 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP2486009B1 (en) 2009-10-06 2019-08-21 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2792646C (en) 2010-03-26 2018-11-20 Galderma Research & Development Improved uses and compositions for safe and effective treatment of erythema
KR20130010122A (ko) 2010-03-26 2013-01-25 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
KR20130041803A (ko) 2010-04-07 2013-04-25 알러간, 인코포레이티드 안과 조성물을 위한 보존제의 조합
AU2011237677A1 (en) 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
US10213431B2 (en) 2010-07-29 2019-02-26 Allergan, Inc. Preservative free brimonidine and timolol solutions
US20130261126A1 (en) 2010-10-21 2013-10-03 Galderma S.A. Brimonidiine gel compositions and methods of use
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2843251A1 (en) 2011-07-25 2013-01-31 Santosh C. Sinha N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0775134A1 (en) * 1994-08-04 1997-05-28 Synaptic Pharmaceutical Corporation Imidazolin-2-ylaminobenzimidazole derivatives
EP0775134A4 (en) * 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES

Also Published As

Publication number Publication date
NL159102B (nl) 1979-01-15
AU5198573A (en) 1974-08-08
JPS5754516B2 (ru) 1982-11-18
CH576975A5 (ru) 1976-06-30
JPS5745439B2 (ru) 1982-09-28
SE417204B (sv) 1981-03-02
US3890319A (en) 1975-06-17
ES411804A1 (es) 1976-05-01
FI63757C (fi) 1983-08-10
FR2181776B1 (ru) 1976-08-13
IE37519B1 (en) 1977-08-17
FI63757B (fi) 1983-04-29
CA981678A (en) 1976-01-13
ES412102A1 (es) 1976-05-16
GB1381979A (en) 1975-01-29
AR213705A1 (es) 1979-03-15
JPS4897878A (ru) 1973-12-13
AU471598B2 (en) 1976-04-29
JPS5625176A (en) 1981-03-10
MX3042E (es) 1980-03-04
IE37519L (en) 1973-08-29
NL7302799A (ru) 1973-08-31
CH577500A5 (ru) 1976-07-15
BE795970A (fr) 1973-08-27
DE2309160A1 (de) 1973-09-27

Similar Documents

Publication Publication Date Title
FR2181776A1 (ru)
CS166665B2 (ru)
CS168466B2 (ru)
CS157938B1 (ru)
CS172471B1 (ru)
CH569667A5 (ru)
CH598205A5 (ru)
BG21183A3 (ru)
CH574329A5 (ru)
BG22277A1 (ru)
CH1392072A4 (ru)
CH464372A4 (ru)
CH545744A (ru)
CH545864A (ru)
CH554968A (ru)
CH560001A5 (ru)
CH560333A5 (ru)
CH562124A5 (ru)
CH586684A5 (ru)
CH566910A5 (ru)
CH567054A5 (ru)
CH567560A5 (ru)
AU479494A (ru)
CH569147A5 (ru)
CH587367A5 (ru)

Legal Events

Date Code Title Description
ST Notification of lapse